Literature DB >> 9818662

Change in body fat, but not body weight or metabolic correlates of obesity, is related to symptomatic relief of obese patients with knee osteoarthritis after a weight control program.

Y Toda1, T Toda, S Takemura, T Wada, T Morimoto, R Ogawa.   

Abstract

OBJECTIVE: To determine the variable most closely related to symptomatic relief of osteoarthritis (OA) of the knee in response to a weight control program.
METHODS: Twenty-two patients diagnosed with knee OA whose body mass index (BMI) was more than 26.4 were treated with a low calorie diet, an appetite suppressant, and nonsteroidal antiinflammatory drugs for 6 weeks. The patients were instructed to follow a walking program. We analyzed BMI, percent body fat, the average number of steps per day by pedometer, and the metabolic correlates of obesity (blood pressure, fasting blood serum glucose, total cholesterol, triglycerides, and serum insulin) at the beginning and end of therapy. The correlation between the change in each variable and the remission score (delta score) using the Severity Index of Lequesne, et al was evaluated.
RESULTS: Delta score of knee OA was more strongly associated with reduction in percent body fat (p= 0.0013, r=0.62) than other variables. Significant correlation was also observed between the number of steps per day and delta score (p=0.0031, r=-0.58). No other variable, including weight loss, was significantly correlated with delta score. There was a significant correlation between delta percent body fat and the number of steps per day (p=0.012, r=-0.62).
CONCLUSION: In a weight control program, decreasing body fat and increasing physical activity are more important than body weight loss or decreasing other indices of obesity in producing symptomatic relief of knee OA, although there is not necessarily a cause and effect relationship between body fat and OA score.

Entities:  

Mesh:

Year:  1998        PMID: 9818662

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  40 in total

Review 1.  Recent advances: rheumatology.

Authors:  R Madhok; H Kerr; H A Capell
Journal:  BMJ       Date:  2000-10-07

Review 2.  [Conservative treatment of knee osteoarthritis].

Authors:  H Madry; D Kohn
Journal:  Unfallchirurg       Date:  2004-08       Impact factor: 1.000

Review 3.  Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis.

Authors:  Robin Christensen; Else Marie Bartels; Arne Astrup; Henning Bliddal
Journal:  Ann Rheum Dis       Date:  2007-01-04       Impact factor: 19.103

4.  Obesity and osteoarthritis: more complex than predicted!

Authors:  P Pottie; N Presle; B Terlain; P Netter; D Mainard; F Berenbaum
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 5.  Innate Immune Responses and Osteoarthritis.

Authors:  Evangelia Kalaitzoglou; Timothy M Griffin; Mary Beth Humphrey
Journal:  Curr Rheumatol Rep       Date:  2017-08       Impact factor: 4.592

Review 6.  Are there promising biologic therapies for osteoarthritis?

Authors:  David J Hunter
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

Review 7.  Biomechanical factors in osteoarthritis.

Authors:  Farshid Guilak
Journal:  Best Pract Res Clin Rheumatol       Date:  2011-12       Impact factor: 4.098

8.  Development of a dosing strategy for enoxaparin in obese patients.

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

Review 9.  Tackling obesity in knee osteoarthritis.

Authors:  Anita E Wluka; Cate B Lombard; Flavia M Cicuttini
Journal:  Nat Rev Rheumatol       Date:  2012-12-18       Impact factor: 20.543

10.  Obesity affects the chondrocyte responsiveness to leptin in patients with osteoarthritis.

Authors:  Stéphane Pallu; Pierre-Jean Francin; Cécile Guillaume; Pascale Gegout-Pottie; Patrick Netter; Didier Mainard; Bernard Terlain; Nathalie Presle
Journal:  Arthritis Res Ther       Date:  2010-06-09       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.